Celldex Therapeutics (CLDX) Tops Q1 EPS by 3c

Celldex Therapeutics (NASDAQ: CLDX) reported Q1 EPS of ($0.33), $0.03 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $406 thousand versus the consensus estimate of $460 thousand.

For earnings history and earnings-related data on (CLDX) click here.

You May Also Be Interested In

• FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
• Morgan Stanley lifts server market TAM to $809B, boosts targets on compute stocks
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance